Bioterrorism

Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement under BARDA Project BioShield Contract

Retrieved on: 
Tuesday, March 5, 2024
Human services, Anthrax, Soil, FDA, Shanda, NHP, PEP, Survival rate, Administration, Post-exposure prophylaxis, Observation, Death, Bioterrorism, Infection, Tablet, Development, Partnership, Pharmaceutical industry

Anthrax (B. anthracis) is an infectious disease caused by gram-positive, rod-shaped, spore-forming bacteria that can lead to severe illness and death.

Key Points: 
  • Anthrax (B. anthracis) is an infectious disease caused by gram-positive, rod-shaped, spore-forming bacteria that can lead to severe illness and death.
  • Oral NUZYRA tablets associated with this procurement were manufactured in the United States as part of the company’s U.S. onshoring efforts.
  • “This procurement also represents a significant milestone in the company’s onshoring efforts as for the first time Paratek is providing BARDA with NUZYRA tablets produced on U.S. soil.
  • In December 2019, BARDA awarded Paratek a contract (75A50120C00001) that is now valued at up to approximately $304 million.

To Save the Profession, Physicians Must Learn from the COVID Response, States AAPS President

Retrieved on: 
Tuesday, December 12, 2023
AAPS, United Nations Security Council, Physician, FDA, Federal Emergency Management Agency, Bioterrorism, COVID, COVID-19, FEMA, Task force, Public, Weapon, Patient, Medicine, Viral, Journal, Hysteria

Dr. Hughes serves as president of the Association of American Physicians and Surgeons (AAPS).

Key Points: 
  • Dr. Hughes serves as president of the Association of American Physicians and Surgeons (AAPS).
  • Tragically, these measures not only failed to stop the viral infection, but they caused incalculable harm, especially to our children.
  • “Media censorship played a huge role in fomenting mass COVID hysteria, which resulted in an almost unquestioning acceptance of tyrannical measures….
  • The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS) , a national organization representing physicians in all specialties since 1943.

Zeteo Tech Awarded $1.87M DHS Science & Technology Directorate Contract to Develop and Test the Next Generation of the digitalMALDI® Real-Time Biological Threat Detection Technology

Retrieved on: 
Tuesday, December 12, 2023
Other Transport, Security, Defense, Other Science, Transport, Research, Other Technology, Other Defense, Other Policy Issues, Building Systems, Hardware, Homeland Security, Other Construction & Property, Science, Technology, Public Policy, Government, Construction & Property, General Health, Health, Bioterrorism, Bacteria, Virus, Biomarker, DHS, Vaccine

This new contract will fund the development and testing of digitalMALDI®, Zeteo Tech’s next generation of sensor technology that enables real-time detection of aerosolized biological-threat agents that include bacteria, viruses, and toxins.

Key Points: 
  • This new contract will fund the development and testing of digitalMALDI®, Zeteo Tech’s next generation of sensor technology that enables real-time detection of aerosolized biological-threat agents that include bacteria, viruses, and toxins.
  • This next generation device takes advantage of technological breakthroughs made by the Zeteo Tech, Inc. team during a previous DHS contract.
  • Both contracts were awarded in support of the Department’s Science and Technology Directorate (S&T).
  • Current systems can require up to 12-36 hours to detect an aerosolized biological threat agent and are costly to operate.

ATCC Announces Comprehensive and Rapid Response to NIAID Research Programs (CARRRP) Award from NIAID

Retrieved on: 
Tuesday, November 28, 2023
Research, Infectious Diseases, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, NIAID, Disease, Acquisition, Vaccine Research Center, VRC, NIH Intramural Research Program, Air tasking order, Bioterrorism, Vaccine, Laboratory, DVM, IDIQ, API, Infection, COVID-19, Biomedical Research, NIH, MBA, Indefinite, Comprehensive, CGMP, Doctor of Philosophy, Active ingredient, Bangladesh Technical Education Board, Public, IRP, Pharmaceutical industry, ATCC

The Task Order is part of the Storage Facility Task Area under the Comprehensive and Rapid Response to NIAID Research Programs (CARRRP).

Key Points: 
  • The Task Order is part of the Storage Facility Task Area under the Comprehensive and Rapid Response to NIAID Research Programs (CARRRP).
  • NIAID’s CARRRP provides the capacity and capability for a broad range of services necessary to support and conduct comprehensive and rapid biomedical research.
  • Under the CARRRP Task Order, ATCC will manage critical biomaterials for the Vaccine Research Center (VRC), one of the three intramural divisions of NIAID’s Intramural Research Program (IRP).
  • “We look forward to working with NIAID and its Intramural Research Program as part of the CARRRP.”

The World's First "Recombinant Anthrax Vaccine": GC Biopharma applies for MFDS Approval

Retrieved on: 
Monday, November 6, 2023
MFDS, Korea Disease Control and Prevention Agency, KDCA, Incidence, Infection, Vaccine, Bioterrorism, Bacillus anthracis, Research, Cell, Protein, Volunteering, Development, Korean Ministry of Culture, Disulfiram-like drug, Phase, Antibody, Marketing, Medicine, Public, Anthrax, Safety, Public and private bills, DNA, Food

YONGIN, South Korea, Nov. 5, 2023 /PRNewswire/ -- GC Biopharma announced 1 Nov. 2023 that it has applied for the marketing approval of "GC1109", an anthrax vaccine jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA), to the Korean Ministry of Food and Drug Safety (MFDS).

Key Points: 
  • YONGIN, South Korea, Nov. 5, 2023 /PRNewswire/ -- GC Biopharma announced 1 Nov. 2023 that it has applied for the marketing approval of "GC1109", an anthrax vaccine jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA), to the Korean Ministry of Food and Drug Safety (MFDS).
  • If approved, "GC1109" will be the world's first recombinant anthrax vaccine.
  • In order to prepare against potential bioterrorism and consequent national crisis, GC Biopharma, under the research project supported by KDCA, has been working on developing a recombinant vaccine for anthrax since 2002.
  • GC Biopharma stated, "We believe in the significance of our journey to localize the anthrax vaccine in terms of securing vaccine sovereignty, while promoting public health and national security.

Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy

Retrieved on: 
Wednesday, October 25, 2023
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology, IND, Bioterrorism, Investigational New Drug, Infection, Francisella tularensis, Drug development, Pharming, DTRA, Defense Threat Reduction Agency, Partnership, TSX, Tularemia, Pharmaceutical industry, USAFA

ATI-1701 is the Company’s potential first-in-class vaccine candidate for the prevention of infection with Francisella tularensis, the causative agent of tularemia and a top-priority biothreat.

Key Points: 
  • ATI-1701 is the Company’s potential first-in-class vaccine candidate for the prevention of infection with Francisella tularensis, the causative agent of tularemia and a top-priority biothreat.
  • With this additional 6.6 million award, Appili’s ATI-1701 program has been awarded the total US$14 million in USAFA funding commitments announced on May 8, 2023.
  • In May 2023, Appili was awarded the first stage of funding commitment from USAFA of US$7.3 million.
  • Appili has also entered into an agreement with its lender whereby if needed, Appili has obtained temporary waivers of a minimum cash balance requirement.

Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax

Retrieved on: 
Monday, July 10, 2023
Post-exposure prophylaxis, ASPR, PEP, Biomedical Advanced Research and Development Authority, U.S. Department of Defense Strategy for Operating in Cyberspace, Human services, Public, Office of Inspector General, U.S. Department of Health and Human Services, Government, Administration, Development, Anthrax, Shanda, Administration for Strategic Preparedness and Response, Bioterrorism, Rabbit, FDA, BARDA, Vaccine

BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced a modification to its Project BioShield contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. The modification provides new development milestones associated with the achievement of specific anthrax development milestones for the next BARDA procurement of NUZYRA® (omadacycline).

Key Points: 
  • The modification provides new development milestones associated with the achievement of specific anthrax development milestones for the next BARDA procurement of NUZYRA® (omadacycline).
  • BARDA and Paratek have agreed the next procurement of NUZYRA anthrax treatment courses will be split into two equal procurements based on the achievement of specific development milestones toward both treatment and post-exposure prophylaxis (PEP) indications of pulmonary anthrax.
  • The trigger for the final procurement of NUZYRA continues to be Paratek’s receipt of sNDA approval from the FDA for the treatment of inhalation anthrax.
  • The company will provide further specificity on these timelines as the anthrax development program progresses.

T2 Biosystems Announces Conversion of Approximately Twenty Percent of CRG Term Loan into Equity

Retrieved on: 
Thursday, July 6, 2023
Growth, BioSystems, CRG, Venture round, Bioterrorism, Security (finance)

LEXINGTON, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the conversion of approximately 20% of its term loan with entities affiliated with CRG Servicing LLC (“CRG”) into T2 Biosystems common stock and Series B convertible preferred stock.

Key Points: 
  • LEXINGTON, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the conversion of approximately 20% of its term loan with entities affiliated with CRG Servicing LLC (“CRG”) into T2 Biosystems common stock and Series B convertible preferred stock.
  • The conversion reduces the outstanding principal amount of the term loan by $10 million, or approximately 20%, in exchange for 48,345,798 shares of T2 Biosystems common stock and Series B Convertible Preferred Stock convertible into 93,297,259 shares of common stock, based on the June 30, 2023 close of business price of $0.0706 per share.
  • The December 30, 2024 interest-only period end and maturity date of the term loan is unchanged.
  • Following this transaction, CRG is now a 19.99% beneficial owner of T2 Biosystems’ outstanding common stock.

Global Biodefence Market Report 2023: Increasing List of Bio-threat Agents Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 13, 2023
Pharmaceutical, Health, Defense, Other Defense, Vaccine, Travel, Internet, Anxiety, Infection, Bioterrorism, Biological warfare, Clinical epidemiology, Government, Market, Death, Botulism, Investment, Developed country, Economic development, R, Anthrax, News, Social media, Clothing, Video game, Fine chemical, Renewable energy, Beauty salon, Sales, Biodefense

The "Biodefence Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biodefence Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • Increasing awareness regarding bioterrorism attacks in developed as well as underdeveloped economies will significantly fuel the biodefence market growth over the forecast period.
  • Minimal government intervention and low R&D funding in underdeveloped regions will impede the biodefence market growth over the forecast period.
  • Where is the Biodefence Market heading and how can you ensure you are at the forefront of the market?

New Report Measures States' Emergency Preparedness and Makes Recommendations About How to Strengthen the Nation's Public Health System

Retrieved on: 
Wednesday, May 24, 2023
Vaccine, Trust for America's Health, Prevalence, Vaccination, Microsoft, Public, COVID-19, Policy, Infection, Health, Health equity, MSCE, Administration, Congress, Death, Hospital, Climate change, MCM, Water, Weather, Transport, Pharmaceutical industry, Management, Health insurance, Disaster, Trust, Bioterrorism

WASHINGTON, May 24, 2023 /PRNewswire/ -- As infectious disease outbreaks and extreme weather events threaten the health of more Americans, a new report shows the need for strengthened national and state public health emergency preparedness.

Key Points: 
  • The report tiers states and the District of Columbia into three performance levels for health emergency preparedness: high, middle, and low.
  • "Increased and sustained investment in public health infrastructure, emergency preparedness, and health equity will save lives," said J. Nadine Gracia, M.D., MSCE, President and CEO of Trust for America's Health.
  • The report contains recommendations for policy actions that would create a stronger public health system at all levels, including:
    The Administration, Congress, and state lawmakers should modernize public health infrastructure, including by investing $4.5 billion annually to support foundational public health capabilities.
  • Policymakers at all levels should act to protect and strengthen public health authorities and should prioritize rebuilding trust in public health agencies and leaders.